Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

NCT04536558 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

352

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

Interventions

DRUG: olanzapine plus fosaprepitant-based triple regimen
DRUG: placebo plus fosaprepitant-based triple regimen

Sponsor

Sun Yat-sen University

Collaborators

[object Object]